| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peripheral Arterial Disease | 34 | 2024 | 96 | 8.830 |
Why?
|
| Coronary Artery Disease | 15 | 2024 | 362 | 4.540 |
Why?
|
| Cardiovascular Diseases | 25 | 2024 | 713 | 4.360 |
Why?
|
| Vascular Calcification | 12 | 2024 | 51 | 4.190 |
Why?
|
| Exercise Therapy | 15 | 2023 | 81 | 3.200 |
Why?
|
| Walking | 21 | 2024 | 92 | 3.030 |
Why?
|
| Coronary Vessels | 9 | 2022 | 192 | 2.920 |
Why?
|
| Walk Test | 13 | 2024 | 24 | 2.590 |
Why?
|
| Exercise | 8 | 2024 | 325 | 2.520 |
Why?
|
| Exercise Test | 8 | 2022 | 166 | 2.200 |
Why?
|
| Myocardial Infarction | 14 | 2024 | 374 | 2.160 |
Why?
|
| Atherosclerosis | 9 | 2024 | 257 | 2.150 |
Why?
|
| Blood Pressure | 14 | 2024 | 901 | 1.860 |
Why?
|
| Ankle Brachial Index | 13 | 2024 | 28 | 1.860 |
Why?
|
| Coronary Disease | 5 | 2024 | 260 | 1.790 |
Why?
|
| Lower Extremity | 11 | 2022 | 88 | 1.790 |
Why?
|
| Calcium | 8 | 2022 | 1175 | 1.680 |
Why?
|
| Exercise Tolerance | 6 | 2024 | 54 | 1.400 |
Why?
|
| Platelet Aggregation Inhibitors | 9 | 2024 | 144 | 1.400 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2024 | 377 | 1.360 |
Why?
|
| Aspirin | 11 | 2024 | 160 | 1.140 |
Why?
|
| Stroke | 13 | 2024 | 987 | 1.130 |
Why?
|
| Intermittent Claudication | 5 | 2023 | 20 | 1.130 |
Why?
|
| Humans | 112 | 2024 | 89435 | 1.120 |
Why?
|
| Evidence-Based Medicine | 6 | 2018 | 433 | 1.090 |
Why?
|
| Aged | 57 | 2024 | 19185 | 1.080 |
Why?
|
| Heart Failure | 7 | 2022 | 1186 | 1.080 |
Why?
|
| Muscle, Skeletal | 7 | 2024 | 469 | 1.080 |
Why?
|
| Antihypertensive Agents | 6 | 2023 | 251 | 1.050 |
Why?
|
| Calcinosis | 2 | 2022 | 230 | 1.030 |
Why?
|
| Hypertension | 9 | 2024 | 746 | 1.010 |
Why?
|
| Menstruation Disturbances | 1 | 2023 | 24 | 0.900 |
Why?
|
| Menstrual Cycle | 1 | 2023 | 54 | 0.880 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2023 | 192 | 0.880 |
Why?
|
| Practice Guidelines as Topic | 7 | 2024 | 1048 | 0.880 |
Why?
|
| Metabolic Diseases | 1 | 2023 | 50 | 0.860 |
Why?
|
| Cardiology | 7 | 2018 | 115 | 0.860 |
Why?
|
| Secondary Prevention | 7 | 2024 | 158 | 0.850 |
Why?
|
| Cholesterol | 4 | 2018 | 359 | 0.850 |
Why?
|
| Kidney Diseases | 2 | 2019 | 320 | 0.840 |
Why?
|
| Female | 66 | 2024 | 46264 | 0.840 |
Why?
|
| Risk Factors | 23 | 2024 | 5499 | 0.820 |
Why?
|
| Male | 63 | 2024 | 42455 | 0.800 |
Why?
|
| Leg | 5 | 2023 | 140 | 0.790 |
Why?
|
| Middle Aged | 49 | 2024 | 26008 | 0.790 |
Why?
|
| Femoral Artery | 3 | 2017 | 84 | 0.750 |
Why?
|
| Diabetic Angiopathies | 2 | 2012 | 37 | 0.740 |
Why?
|
| Plaque, Atherosclerotic | 3 | 2017 | 60 | 0.720 |
Why?
|
| Randomized Controlled Trials as Topic | 11 | 2023 | 839 | 0.670 |
Why?
|
| Cardiotoxicity | 1 | 2019 | 10 | 0.660 |
Why?
|
| Fibrinolytic Agents | 1 | 2021 | 217 | 0.650 |
Why?
|
| Masked Hypertension | 1 | 2018 | 1 | 0.650 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2019 | 329 | 0.650 |
Why?
|
| Panic Disorder | 1 | 2018 | 21 | 0.650 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2018 | 29 | 0.640 |
Why?
|
| Obesity | 3 | 2023 | 971 | 0.640 |
Why?
|
| Weight Gain | 1 | 2019 | 119 | 0.630 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2019 | 2664 | 0.590 |
Why?
|
| Legislation, Food | 1 | 2017 | 1 | 0.590 |
Why?
|
| Trans Fatty Acids | 1 | 2017 | 1 | 0.590 |
Why?
|
| Weight Loss | 1 | 2019 | 227 | 0.590 |
Why?
|
| Predictive Value of Tests | 11 | 2024 | 1725 | 0.590 |
Why?
|
| Mitochondria, Muscle | 3 | 2024 | 27 | 0.570 |
Why?
|
| Diabetes Mellitus | 4 | 2024 | 742 | 0.570 |
Why?
|
| Diet | 2 | 2017 | 443 | 0.550 |
Why?
|
| Smoking | 3 | 2017 | 622 | 0.540 |
Why?
|
| Myocardial Revascularization | 1 | 2016 | 30 | 0.540 |
Why?
|
| Mass Screening | 2 | 2012 | 637 | 0.530 |
Why?
|
| Arteries | 1 | 2017 | 180 | 0.520 |
Why?
|
| Home Care Services | 1 | 2016 | 73 | 0.510 |
Why?
|
| Risk Assessment | 13 | 2024 | 2306 | 0.510 |
Why?
|
| Coronary Angiography | 4 | 2024 | 242 | 0.510 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2023 | 219 | 0.500 |
Why?
|
| Hospitalization | 5 | 2024 | 877 | 0.500 |
Why?
|
| Breast | 1 | 2017 | 292 | 0.490 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 162 | 0.490 |
Why?
|
| Aged, 80 and over | 15 | 2024 | 6816 | 0.470 |
Why?
|
| Body Mass Index | 2 | 2017 | 773 | 0.470 |
Why?
|
| Ischemia | 4 | 2021 | 251 | 0.470 |
Why?
|
| Pharmacogenetics | 4 | 2019 | 443 | 0.460 |
Why?
|
| C-Reactive Protein | 5 | 2018 | 192 | 0.460 |
Why?
|
| Mobility Limitation | 4 | 2023 | 20 | 0.460 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2022 | 51 | 0.450 |
Why?
|
| American Heart Association | 4 | 2018 | 95 | 0.450 |
Why?
|
| Mammography | 1 | 2017 | 474 | 0.440 |
Why?
|
| Cardiac-Gated Imaging Techniques | 1 | 2013 | 21 | 0.440 |
Why?
|
| Particulate Matter | 2 | 2024 | 102 | 0.440 |
Why?
|
| Blood Transfusion | 2 | 2024 | 169 | 0.430 |
Why?
|
| Blood Glucose | 1 | 2017 | 837 | 0.430 |
Why?
|
| Anemia | 2 | 2024 | 130 | 0.430 |
Why?
|
| Time Factors | 10 | 2024 | 5340 | 0.410 |
Why?
|
| Prevalence | 5 | 2022 | 1243 | 0.410 |
Why?
|
| Biomarkers | 10 | 2024 | 1769 | 0.400 |
Why?
|
| Clinical Decision-Making | 3 | 2019 | 282 | 0.390 |
Why?
|
| Medicare | 3 | 2023 | 425 | 0.390 |
Why?
|
| United States | 18 | 2024 | 7003 | 0.380 |
Why?
|
| Albuminuria | 1 | 2010 | 48 | 0.360 |
Why?
|
| Anticholesteremic Agents | 3 | 2018 | 141 | 0.360 |
Why?
|
| Troponin T | 2 | 2021 | 39 | 0.350 |
Why?
|
| Tunica Intima | 2 | 2010 | 60 | 0.340 |
Why?
|
| Hemorrhage | 7 | 2024 | 280 | 0.340 |
Why?
|
| Treatment Outcome | 11 | 2024 | 8251 | 0.340 |
Why?
|
| Risk Reduction Behavior | 2 | 2018 | 97 | 0.330 |
Why?
|
| Dyslipidemias | 2 | 2024 | 107 | 0.330 |
Why?
|
| Ankle | 1 | 2009 | 20 | 0.330 |
Why?
|
| Brachial Artery | 1 | 2009 | 36 | 0.330 |
Why?
|
| Blood Pressure Determination | 1 | 2009 | 60 | 0.320 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2009 | 61 | 0.320 |
Why?
|
| Thiazolidinediones | 1 | 2009 | 73 | 0.320 |
Why?
|
| Drug Therapy, Combination | 3 | 2024 | 784 | 0.320 |
Why?
|
| Incidence | 4 | 2022 | 1597 | 0.310 |
Why?
|
| DNA, Mitochondrial | 2 | 2020 | 187 | 0.310 |
Why?
|
| Erectile Dysfunction | 1 | 2009 | 75 | 0.310 |
Why?
|
| Lipids | 4 | 2023 | 272 | 0.310 |
Why?
|
| Adult | 15 | 2024 | 26646 | 0.310 |
Why?
|
| Research Design | 4 | 2023 | 600 | 0.310 |
Why?
|
| Niacin | 1 | 2008 | 37 | 0.310 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2019 | 112 | 0.310 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 2415 | 0.300 |
Why?
|
| Cohort Studies | 8 | 2024 | 2875 | 0.290 |
Why?
|
| Hypolipidemic Agents | 1 | 2008 | 99 | 0.290 |
Why?
|
| Cardiomyopathies | 1 | 2010 | 264 | 0.290 |
Why?
|
| Overweight | 2 | 2019 | 119 | 0.280 |
Why?
|
| Drug Prescriptions | 2 | 2019 | 144 | 0.280 |
Why?
|
| Hypoglycemic Agents | 1 | 2009 | 349 | 0.270 |
Why?
|
| Air Pollution | 2 | 2024 | 92 | 0.270 |
Why?
|
| Heart Rate | 2 | 2020 | 496 | 0.260 |
Why?
|
| Follow-Up Studies | 8 | 2023 | 3667 | 0.260 |
Why?
|
| Clinical Trials as Topic | 3 | 2022 | 1150 | 0.260 |
Why?
|
| Stroke Volume | 3 | 2024 | 463 | 0.250 |
Why?
|
| Acute Coronary Syndrome | 2 | 2023 | 30 | 0.250 |
Why?
|
| Environmental Exposure | 2 | 2024 | 322 | 0.250 |
Why?
|
| Cell Respiration | 1 | 2024 | 19 | 0.240 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2017 | 275 | 0.240 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 1843 | 0.230 |
Why?
|
| Income | 1 | 2024 | 84 | 0.230 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2024 | 105 | 0.230 |
Why?
|
| Carotid Arteries | 3 | 2010 | 134 | 0.230 |
Why?
|
| Weight Reduction Programs | 1 | 2023 | 13 | 0.220 |
Why?
|
| Oxygen Consumption | 1 | 2024 | 245 | 0.220 |
Why?
|
| Chicago | 7 | 2023 | 1428 | 0.220 |
Why?
|
| Disease Progression | 5 | 2020 | 1489 | 0.220 |
Why?
|
| Cholesterol, LDL | 1 | 2024 | 226 | 0.210 |
Why?
|
| Pharmacogenomic Testing | 3 | 2019 | 98 | 0.210 |
Why?
|
| Recovery of Function | 2 | 2021 | 293 | 0.210 |
Why?
|
| Insurance Coverage | 1 | 2023 | 120 | 0.210 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2022 | 46 | 0.210 |
Why?
|
| Case-Control Studies | 4 | 2024 | 1862 | 0.210 |
Why?
|
| Life Style | 2 | 2014 | 173 | 0.200 |
Why?
|
| Quality of Life | 3 | 2021 | 1669 | 0.200 |
Why?
|
| Primary Prevention | 1 | 2022 | 82 | 0.200 |
Why?
|
| Longitudinal Studies | 6 | 2024 | 1072 | 0.200 |
Why?
|
| Precision Medicine | 4 | 2019 | 412 | 0.190 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2021 | 8 | 0.190 |
Why?
|
| Dementia | 1 | 2023 | 195 | 0.190 |
Why?
|
| Dependent Ambulation | 2 | 2017 | 3 | 0.190 |
Why?
|
| Chronic Disease | 1 | 2024 | 950 | 0.190 |
Why?
|
| Prospective Studies | 6 | 2021 | 4297 | 0.180 |
Why?
|
| Ribose | 1 | 2020 | 17 | 0.180 |
Why?
|
| Rest | 1 | 2020 | 49 | 0.180 |
Why?
|
| Glucose | 1 | 2023 | 630 | 0.180 |
Why?
|
| Prediabetic State | 1 | 2020 | 36 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2009 | 1177 | 0.180 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 91 | 0.180 |
Why?
|
| Endovascular Procedures | 1 | 2024 | 277 | 0.180 |
Why?
|
| Chocolate | 1 | 2020 | 1 | 0.180 |
Why?
|
| Residence Characteristics | 2 | 2022 | 202 | 0.180 |
Why?
|
| Recommended Dietary Allowances | 1 | 2019 | 2 | 0.180 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2020 | 52 | 0.180 |
Why?
|
| Cholesterol, Dietary | 1 | 2019 | 27 | 0.180 |
Why?
|
| Nutrition Policy | 1 | 2019 | 13 | 0.170 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 1720 | 0.170 |
Why?
|
| Health Status Disparities | 2 | 2024 | 188 | 0.170 |
Why?
|
| Catechin | 1 | 2020 | 24 | 0.170 |
Why?
|
| Point-of-Care Systems | 2 | 2019 | 147 | 0.170 |
Why?
|
| Double-Blind Method | 5 | 2023 | 1720 | 0.170 |
Why?
|
| Diet, Western | 1 | 2019 | 38 | 0.170 |
Why?
|
| Socioeconomic Factors | 2 | 2024 | 588 | 0.170 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2017 | 104 | 0.170 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2017 | 39 | 0.170 |
Why?
|
| Muscle Strength | 1 | 2019 | 31 | 0.170 |
Why?
|
| Kidney Function Tests | 1 | 2019 | 114 | 0.160 |
Why?
|
| Anthracyclines | 1 | 2019 | 38 | 0.160 |
Why?
|
| Retrospective Studies | 6 | 2019 | 9064 | 0.160 |
Why?
|
| Echocardiography | 3 | 2010 | 937 | 0.160 |
Why?
|
| Disease Management | 2 | 2019 | 329 | 0.160 |
Why?
|
| Prescription Drugs | 1 | 2019 | 36 | 0.160 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 2760 | 0.160 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2019 | 118 | 0.160 |
Why?
|
| Organ Size | 1 | 2019 | 370 | 0.160 |
Why?
|
| Hyperlipidemias | 1 | 2018 | 92 | 0.150 |
Why?
|
| Insulin | 1 | 2023 | 1147 | 0.150 |
Why?
|
| Home Nursing | 1 | 2018 | 19 | 0.150 |
Why?
|
| Sensitivity and Specificity | 5 | 2015 | 2015 | 0.150 |
Why?
|
| Necrosis | 2 | 2017 | 209 | 0.150 |
Why?
|
| Wearable Electronic Devices | 1 | 2018 | 26 | 0.150 |
Why?
|
| Cholesterol, HDL | 2 | 2009 | 168 | 0.150 |
Why?
|
| Electronic Health Records | 2 | 2021 | 350 | 0.150 |
Why?
|
| Young Adult | 3 | 2023 | 6322 | 0.150 |
Why?
|
| Physical Endurance | 1 | 2017 | 10 | 0.150 |
Why?
|
| Risk | 2 | 2021 | 657 | 0.150 |
Why?
|
| Collateral Circulation | 1 | 2017 | 35 | 0.150 |
Why?
|
| Comorbidity | 3 | 2018 | 951 | 0.150 |
Why?
|
| Hypercholesterolemia | 1 | 2018 | 159 | 0.150 |
Why?
|
| Anxiety Disorders | 1 | 2018 | 152 | 0.150 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2020 | 216 | 0.150 |
Why?
|
| Databases, Factual | 2 | 2021 | 856 | 0.150 |
Why?
|
| New York | 1 | 2017 | 72 | 0.140 |
Why?
|
| Advisory Committees | 1 | 2017 | 90 | 0.140 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 28 | 0.140 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 177 | 0.140 |
Why?
|
| Fasting | 1 | 2017 | 163 | 0.140 |
Why?
|
| Educational Status | 1 | 2017 | 195 | 0.140 |
Why?
|
| Biopsy | 4 | 2024 | 1185 | 0.140 |
Why?
|
| Prognosis | 5 | 2022 | 3788 | 0.130 |
Why?
|
| Antioxidants | 1 | 2017 | 226 | 0.130 |
Why?
|
| Regression Analysis | 1 | 2017 | 590 | 0.130 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 1714 | 0.130 |
Why?
|
| Family Health | 1 | 2016 | 162 | 0.130 |
Why?
|
| Physician's Role | 1 | 2017 | 177 | 0.130 |
Why?
|
| Physician-Patient Relations | 2 | 2019 | 625 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2024 | 1943 | 0.120 |
Why?
|
| Surveys and Questionnaires | 5 | 2020 | 2633 | 0.120 |
Why?
|
| Computed Tomography Angiography | 1 | 2016 | 146 | 0.120 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2010 | 689 | 0.120 |
Why?
|
| Oscillometry | 1 | 2014 | 25 | 0.120 |
Why?
|
| Health Status | 1 | 2017 | 371 | 0.120 |
Why?
|
| Heptanoic Acids | 1 | 2014 | 71 | 0.120 |
Why?
|
| Patient Selection | 1 | 2018 | 684 | 0.120 |
Why?
|
| Random Allocation | 1 | 2014 | 327 | 0.110 |
Why?
|
| Genome, Human | 1 | 2019 | 767 | 0.110 |
Why?
|
| Kidney | 1 | 2019 | 1147 | 0.110 |
Why?
|
| Heart Arrest | 1 | 2017 | 278 | 0.110 |
Why?
|
| Pyrroles | 1 | 2014 | 187 | 0.110 |
Why?
|
| Celiac Disease | 1 | 2016 | 214 | 0.110 |
Why?
|
| Electrocardiography | 1 | 2015 | 496 | 0.110 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2012 | 21 | 0.100 |
Why?
|
| HIV Infections | 1 | 2021 | 840 | 0.100 |
Why?
|
| Child | 1 | 2023 | 7178 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 602 | 0.100 |
Why?
|
| Professional Practice | 1 | 2011 | 46 | 0.100 |
Why?
|
| Uncertainty | 1 | 2012 | 75 | 0.100 |
Why?
|
| Unnecessary Procedures | 1 | 2011 | 51 | 0.100 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 852 | 0.100 |
Why?
|
| Early Diagnosis | 1 | 2011 | 125 | 0.090 |
Why?
|
| Postmenopause | 2 | 2022 | 102 | 0.090 |
Why?
|
| Adolescent | 1 | 2023 | 9270 | 0.090 |
Why?
|
| Patient Education as Topic | 2 | 2011 | 363 | 0.090 |
Why?
|
| Health Promotion | 1 | 2011 | 165 | 0.090 |
Why?
|
| Patient-Centered Care | 2 | 2023 | 209 | 0.080 |
Why?
|
| Europe | 1 | 2010 | 322 | 0.080 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2010 | 56 | 0.080 |
Why?
|
| Peptide Fragments | 2 | 2022 | 463 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 1 | 2010 | 276 | 0.080 |
Why?
|
| Forecasting | 1 | 2010 | 306 | 0.080 |
Why?
|
| Sulfonylurea Compounds | 1 | 2009 | 65 | 0.080 |
Why?
|
| Image Enhancement | 2 | 2010 | 567 | 0.080 |
Why?
|
| Fluorocarbons | 1 | 2009 | 72 | 0.080 |
Why?
|
| Pattern Recognition, Automated | 1 | 2010 | 217 | 0.080 |
Why?
|
| Sex Factors | 2 | 2024 | 1069 | 0.080 |
Why?
|
| Regional Blood Flow | 2 | 2020 | 198 | 0.080 |
Why?
|
| Embolism | 1 | 2008 | 32 | 0.080 |
Why?
|
| Patient Compliance | 2 | 2020 | 231 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 479 | 0.070 |
Why?
|
| Triglycerides | 1 | 2008 | 232 | 0.070 |
Why?
|
| Vascular Surgical Procedures | 2 | 2020 | 149 | 0.070 |
Why?
|
| Attitude to Health | 2 | 2017 | 222 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2009 | 683 | 0.070 |
Why?
|
| Artifacts | 1 | 2009 | 247 | 0.070 |
Why?
|
| Ischemic Attack, Transient | 1 | 2008 | 182 | 0.070 |
Why?
|
| Pulmonary Edema | 1 | 2007 | 50 | 0.070 |
Why?
|
| Consensus | 2 | 2018 | 358 | 0.070 |
Why?
|
| Critical Illness | 2 | 2020 | 306 | 0.060 |
Why?
|
| Logistic Models | 1 | 2009 | 1213 | 0.060 |
Why?
|
| Respiratory Insufficiency | 1 | 2007 | 161 | 0.060 |
Why?
|
| Myocardial Contraction | 1 | 2006 | 252 | 0.060 |
Why?
|
| Oxidative Phosphorylation | 1 | 2024 | 54 | 0.060 |
Why?
|
| Systole | 1 | 2024 | 115 | 0.060 |
Why?
|
| Diastole | 1 | 2024 | 141 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2014 | 3452 | 0.060 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2023 | 4 | 0.060 |
Why?
|
| Algorithms | 2 | 2010 | 1881 | 0.060 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2023 | 6 | 0.060 |
Why?
|
| Brain Ischemia | 1 | 2008 | 400 | 0.060 |
Why?
|
| Ticlopidine | 1 | 2023 | 25 | 0.060 |
Why?
|
| Medically Uninsured | 1 | 2023 | 59 | 0.060 |
Why?
|
| Intensive Care Units | 1 | 2007 | 394 | 0.060 |
Why?
|
| Air Pollutants | 1 | 2024 | 92 | 0.050 |
Why?
|
| Erythrocyte Transfusion | 1 | 2023 | 72 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2023 | 192 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2023 | 162 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2023 | 187 | 0.050 |
Why?
|
| Hypoxia | 1 | 2007 | 653 | 0.050 |
Why?
|
| Seasons | 1 | 2023 | 238 | 0.050 |
Why?
|
| Temperature | 1 | 2023 | 406 | 0.050 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2006 | 516 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2021 | 67 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2023 | 237 | 0.050 |
Why?
|
| Internet | 1 | 2023 | 320 | 0.050 |
Why?
|
| Poly Adenosine Diphosphate Ribose | 1 | 2020 | 5 | 0.050 |
Why?
|
| Medicaid | 1 | 2023 | 232 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 48 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2020 | 56 | 0.050 |
Why?
|
| Recurrence | 1 | 2023 | 1144 | 0.040 |
Why?
|
| Sick Role | 1 | 2000 | 13 | 0.040 |
Why?
|
| ROC Curve | 2 | 2016 | 780 | 0.040 |
Why?
|
| Research Personnel | 1 | 2021 | 71 | 0.040 |
Why?
|
| Beverages | 1 | 2020 | 17 | 0.040 |
Why?
|
| Electron Transport Complex IV | 1 | 2020 | 49 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2021 | 140 | 0.040 |
Why?
|
| Drug Recalls | 1 | 2019 | 13 | 0.040 |
Why?
|
| Models, Psychological | 1 | 2000 | 158 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2020 | 264 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2019 | 125 | 0.040 |
Why?
|
| Medication Therapy Management | 1 | 2018 | 16 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2022 | 352 | 0.040 |
Why?
|
| Urban Population | 1 | 2000 | 225 | 0.040 |
Why?
|
| Communication | 2 | 2019 | 458 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2019 | 171 | 0.040 |
Why?
|
| Telephone | 1 | 2018 | 35 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 160 | 0.040 |
Why?
|
| Research | 1 | 2019 | 252 | 0.040 |
Why?
|
| Research Report | 1 | 2017 | 44 | 0.040 |
Why?
|
| Drug Labeling | 1 | 2017 | 41 | 0.040 |
Why?
|
| Pandemics | 1 | 2023 | 773 | 0.030 |
Why?
|
| Heart Function Tests | 1 | 2016 | 33 | 0.030 |
Why?
|
| Health Personnel | 1 | 2019 | 215 | 0.030 |
Why?
|
| Social Perception | 1 | 2017 | 95 | 0.030 |
Why?
|
| Tomography, Spiral Computed | 1 | 2016 | 77 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2016 | 111 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 337 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2016 | 103 | 0.030 |
Why?
|
| Fibrosis | 1 | 2016 | 234 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2000 | 538 | 0.030 |
Why?
|
| Stem Cells | 1 | 2017 | 372 | 0.030 |
Why?
|
| Telemedicine | 1 | 2018 | 188 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 871 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 860 | 0.030 |
Why?
|
| Heparin | 1 | 1995 | 185 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2018 | 398 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2016 | 579 | 0.030 |
Why?
|
| Herpesvirus 1, Human | 1 | 1995 | 244 | 0.030 |
Why?
|
| Registries | 1 | 2016 | 788 | 0.020 |
Why?
|
| Sample Size | 1 | 2012 | 128 | 0.020 |
Why?
|
| Tunica Media | 1 | 2010 | 16 | 0.020 |
Why?
|
| Shear Strength | 1 | 2010 | 18 | 0.020 |
Why?
|
| Elastic Modulus | 1 | 2010 | 36 | 0.020 |
Why?
|
| Microbubbles | 1 | 2008 | 38 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 576 | 0.020 |
Why?
|
| Ventricular Pressure | 1 | 2007 | 38 | 0.020 |
Why?
|
| Immunoassay | 1 | 2007 | 91 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2007 | 113 | 0.020 |
Why?
|
| Computer Systems | 1 | 2006 | 79 | 0.020 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2008 | 344 | 0.020 |
Why?
|
| Ventricular Function, Right | 1 | 2007 | 146 | 0.020 |
Why?
|
| Cardiac Catheterization | 1 | 2007 | 303 | 0.020 |
Why?
|
| Movement | 1 | 2006 | 309 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2006 | 782 | 0.010 |
Why?
|
| Contrast Media | 1 | 2009 | 1092 | 0.010 |
Why?
|
| Myocardium | 1 | 2006 | 571 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 1598 | 0.010 |
Why?
|
| Nursing Methodology Research | 1 | 2000 | 11 | 0.010 |
Why?
|
| Needs Assessment | 1 | 2000 | 157 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2000 | 170 | 0.010 |
Why?
|
| Viral Plaque Assay | 1 | 1995 | 19 | 0.010 |
Why?
|
| Carbohydrate Sequence | 1 | 1995 | 20 | 0.010 |
Why?
|
| Carbohydrate Conformation | 1 | 1995 | 18 | 0.010 |
Why?
|
| Vero Cells | 1 | 1995 | 103 | 0.010 |
Why?
|
| Virion | 1 | 1995 | 59 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1995 | 413 | 0.010 |
Why?
|
| Kinetics | 1 | 1995 | 1530 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1995 | 672 | 0.010 |
Why?
|
| Cell Line | 1 | 1995 | 2496 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1995 | 3027 | 0.010 |
Why?
|
| Animals | 1 | 1995 | 27396 | 0.000 |
Why?
|